NuVasive, Inc.

NasdaqGS:NUVA Rapport sur les actions

Capitalisation boursière : US$2.1b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

NuVasive Gestion

Gestion contrôle des critères 3/4

Le PDG NuVasive's est Chris Barry, nommé en Nov2018, a un mandat de 4.83 ans. La rémunération annuelle totale est $ 8.08M, composée du salaire de 11.1% et des bonus 88.9%, y compris les actions et options de la société. détient directement 0.14% des actions de la société, d'une valeur de $ 2.90M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.7 ans et 5.6 ans.

Informations clés

Chris Barry

Directeur général

US$8.1m

Rémunération totale

Pourcentage du salaire du PDG11.1%
Durée du mandat du directeur général4.8yrs
Propriété du PDG0.1%
Durée moyenne d'occupation des postes de direction3.7yrs
Durée moyenne du mandat des membres du conseil d'administration5.6yrs

Mises à jour récentes de la gestion

Recent updates

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Apr 18
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

Jan 24
What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Dec 31
NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Dec 05
Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Nov 13
These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Sep 22
Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

Sep 01
Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

Aug 17

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Aug 11
Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

Aug 03

NuVasive: Industry Tailwinds More Than Fairly Priced

Jun 13

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jun 01
Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

May 11
Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Apr 20
NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

Mar 30
At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive's Turnaround Story Needs A Boost From Better Results

Mar 01

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Dec 28
Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

Dec 02
Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Nov 11
NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Oct 21
NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Sep 29
Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

Aug 18
At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

Aug 12

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Jul 27
Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Jun 17
Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

May 30
Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

May 12
Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Mar 30
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Mar 09
Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

Feb 16
Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

Jan 26
A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

NuVasive stock gains on study results of its X360 surgery approach

Jan 06

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Jan 05
What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Analyse de la rémunération des PDG

Comment la rémunération de Chris Barry a-t-elle évolué par rapport aux bénéfices de NuVasive?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2023n/an/a

US$28m

Mar 31 2023n/an/a

US$20m

Dec 31 2022US$8mUS$897k

US$40m

Sep 30 2022n/an/a

-US$20m

Jun 30 2022n/an/a

-US$40m

Mar 31 2022n/an/a

-US$37m

Dec 31 2021US$8mUS$875k

-US$64m

Sep 30 2021n/an/a

-US$26m

Jun 30 2021n/an/a

US$2m

Mar 31 2021n/an/a

-US$50m

Dec 31 2020US$5mUS$735k

-US$37m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

US$61m

Dec 31 2019US$5mUS$800k

US$65m

Sep 30 2019n/an/a

US$48m

Jun 30 2019n/an/a

US$52m

Mar 31 2019n/an/a

US$49m

Dec 31 2018US$5mUS$92k

US$12m

Rémunération vs marché: La rémunération totale de Chris ($USD 8.08M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.62M ).

Rémunération et revenus: La rémunération de Chris a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Chris Barry (50 yo)

4.8yrs

Titularisation

US$8,077,095

Compensation

Mr. J. Christopher Barry, also known as Chris, serves as Chief Executive Officer and Director of NuVasive, Inc., since November 5, 2018. Mr. Barry served commercial and leadership roles at Covidien. He has...


Équipe de direction

NomPositionTitularisationCompensationPropriété
J. Barry
CEO & Director4.8yrsUS$8.08m0.14%
$ 2.9m
Matthew Harbaugh
Principal Accounting Officer3.7yrsUS$2.97m0.020%
$ 418.2k
Dale Wolf
Senior Vice President of Global Operations3.7yrsUS$1.48m0.017%
$ 355.5k
Nathaniel Sisitsky
Senior VP5.3yrsUS$1.54m0.042%
$ 869.2k
Michael Farrington
Senior Vice President of People & Cultureless than a yearUS$1.03m0.0059%
$ 123.8k
Ryan Donahoe
Senior VP & Chief Technology Officer2yrspas de donnéespas de données
Juliet Cunningham
Vice President of Investor Relationsno datapas de donnéespas de données
Sean Freeman
Senior Vice President of Strategy & Corporate Development3.8yrspas de donnéespas de données
Lisa Pecora
Vice President & Head of Global Commercial Finance5.3yrspas de donnéespas de données
Aviva McPherron
Senior Vice President of Information Technology1.7yrspas de donnéespas de données
Tristan Ribar
Vice President5.3yrspas de donnéespas de données

3.7yrs

Durée moyenne de l'emploi

48yo

Âge moyen

Gestion expérimentée: L'équipe de direction de NUVA est considérée comme expérimentée (ancienneté moyenne 3.7 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
J. Barry
CEO & Director4.8yrsUS$8.08m0.14%
$ 2.9m
John DeFord
Independent Director5.6yrsUS$260.01k0%
$ 0
Robert Friel
Independent Director7.6yrsUS$260.01k0%
$ 0
Vickie Capps
Independent Director8.3yrsUS$280.01k0.0038%
$ 79.4k
R. Huennekens
Independent Director4.9yrsUS$260.01k0.0026%
$ 54.0k
Daniel Wolterman
Independent Chair8.2yrsUS$405.01k0%
$ 0
Leslie Norwalk
Independent Director9.3yrsUS$270.01k0.0059%
$ 123.0k
Siddhartha Kadia
Independent Director2.6yrsUS$260.01k0.0071%
$ 148.7k
Amy Raimundo
Independent Director2.1yrsUS$260.01k0%
$ 0

5.6yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de NUVA sont considérés comme expérimentés (ancienneté moyenne 5.6 ans).